Long-Term Survival Outcomes of NCRT With Surgery vs Surgery With Adjuvant Therapy for ESCC

Among patients with locally advanced esophageal squamous cell carcinoma (ESCC), does neoadjuvant chemoradiotherapy (NCRT) followed by surgery improve long-term survival compared with surgery followed by adjuvant therapy (AT)?In this randomized clinical trial of 254 patients with locally advanced ESCC, the 5-year overall survival (OS) was 59.2% in the NCRT group and 59.6% in the AT group, showing no significant difference between the 2 groups.These findings indicate that surgery followed by adjuvant therapy remains a reasonable treatment option for resectable disease, emphasizing the need to identify patients most likely to benefit from NCRT.

Corresponding Author: Yan Miao, MM (miaoyan@scszlyy.org.cn), and Xuefeng Leng, MD, PhD (doc.leng@uestc.edu.cn& Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, No.55, Section 4, South Renmin Road, Chengdu, Sichuan, China.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.